|
BP14016
|
Miltefosine
|
|
|
|
|
Miltefosine is the treatment of visceral and cutaneous leishmaniasis drug, and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.
|
|
BP14015
|
MI-538
|
|
|
|
|
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).
|
|
BP14014
|
MI-503
|
|
|
|
|
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction.
|
|
BP14013
|
MI-463
|
|
|
|
|
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM).
|
|
BP14012
|
MI-2-2
|
|
|
|
|
MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.
|
|
BP14011
|
Methyl-Hesperidin
|
|
|
|
|
Methyl Hesperidin, a flavanone glycoside (flavonoid) (C28H34O15), is abundant in citrus fruits. Its aglycone form is called hesperetin.
|
|
BP14010
|
Methyl cinnamate
|
|
|
|
|
Methyl cinnamate, a tyrosinase inhibitor and a flavoring compound, has antimicrobial, antiadipogenic, vasorelaxant, and anti-inflammatory effects.
|
|
BP14009
|
Menin-MLL inhibitor 20
|
|
|
|
|
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).
|
|
BP14008
|
Mefuparib hydrochloride
|
|
|
|
|
Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro and in vivo. Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective PARP1/2 inhibitor with IC50s of 3.2 nM and 1.9 nM, respectively.
|
|
BP14007
|
ME0328
|
|
|
|
|
ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.
|
|
BP14006
|
HDAC8-IN-1
|
|
|
|
|
MDK-7933 (HDAC8-IN-1) is a HDAC8 inhibitor with an IC50 of 27.2 nM in cancer cell lines. MDK-7933 shows antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5). HDAC8-IN-1 exhibits cytotoxicity against human lung CL1-5 cells without significant cytotoxicity for normal IMR-90 cells.
|
|
BP14005
|
MC2184
|
|
|
|
|
MC2184 is the inhibitor of human recombinant SIRT1.
|
|
BP14004
|
MC1568
|
|
|
|
|
MC1568 is a specific HDAC inhibitor for maize HD1-A (IC50: 100 nM, in a cell-free assay). It is 34-fold more selective for HD1-A than HD1-B.
|
|
BP14003
|
MARK4 inhibitor 1
|
|
|
|
|
MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis. MARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM.
|
|
BP14002
|
Marein
|
|
|
|
|
Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing/counteracting diabetic encephalopathy.
|
|
BP14001
|
Malantide acetate(86555-35-3 free base)
|
|
|
|
|
Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide that is phosphorylated by PKA and is used to measure PKA activity in vitro.
|
|
BP14000
|
MAK683
|
|
|
|
|
MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).
|
|
BP13999
|
MAK-683 hyrochloride
|
|
|
|
|
MAK683 hydrochloride is an inhibitor of embryonic ectodermal development (EED).
|
|
BP13998
|
M‑89
|
|
|
|
|
M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia. M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin.
|
|
BP13997
|
M344
|
|
|
|
|
M344 is a potent HDAC inhibitor with IC50 of 100 nM and able to induce cell differentiation.
|
.gif)
